Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 5Breast 4Gynecologic 3Other hematologic neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Triple Negative Breast Neoplasms 3Breast Neoplasms 2Breast Neoplasms, Male 1Breast Carcinoma In Situ 1

Interventions

Cyclophosphamide 423Trastuzumab 414Paclitaxel 375Docetaxel 314Capecitabine 265Letrozole 262Carboplatin 257Doxorubicin 213Tamoxifen 184Fulvestrant 176Epirubicin 176Radiotherapy 171Anastrozole 164pembrolizumab 152pertuzumab 147Surveys and Questionnaires 145Exercise 142exemestane 128Vinorelbine 127palbociclib 124Bevacizumab 123Magnetic Resonance Spectroscopy 120Blood Specimen Collection 120Drug Therapy 106Albumin-Bound Paclitaxel 105Gemcitabine 99130-nm albumin-bound paclitaxel 98pyrotinib 92eribulin 90Biopsy 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × poly(I).poly(c12,U) × Breast × Clear all
NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1/2 Terminated
5 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04081389 2023-09-11

Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer

Roswell Park Cancer Institute

Phase 1 Completed
9 enrolled 17 charts
Breast

Breast Carcinoma In Situ, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03599453 2023-07-18

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Roswell Park Cancer Institute

Phase EARLY_PHASE1 Completed
8 enrolled
Breast

Triple Negative Breast Neoplasms

NCT01355393 2020-02-10

Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer

University of Washington

Phase 1/2 Completed
50 enrolled
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡